CMT-SORD is a rare, progressive, neuromuscular disease caused by genetic mutations in the sorbitol dehydrogenase enzyme, which is responsible for the metabolism of sorbitol.

About Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) CMT-SORD is a rare, progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons.

About Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) CMT-SORD is a rare, progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons.

Applied Therapeutics to present new clinical data for govorestat in CMT-SORD at 2025 Peripheral Nerve Society Annual Meeting.

TOPLINE: Vitamin D deficiency is independently linked to the risk for diabetic peripheral neuropathy (DPN) by potentially affecting large nerve fibers in older patients with type 2 diabetes (T2D).

Treatment with govorestat was found to be clinically beneficial for patients with sorbitol dehydrogenase (SORD) deficiency, according to interim results from the phase 3 INSPIRE trial.

Sorbitol Dehydrogenase Deficiency (SORD Deficiency) is a rare, progressive, debilitating hereditary neuropathy that affects peripheral nerves and motor neurons.